89bio, Inc/$ETNB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About 89bio, Inc

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Ticker

$ETNB
Primary listing

Industry

Biotechnology

Employees

93

ISIN

US2825591033

89bio, Inc Metrics

BasicAdvanced
$1.5B
-
-$3.30
1.29
-

What the Analysts think about 89bio, Inc

Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.

Bulls say / Bears say

89bio successfully raised approximately $287.5 million in a public offering in January 2025, enhancing its financial position to support ongoing clinical trials and operations. (stocktitan.net)
Analysts have set a consensus price target of $27.56 for 89bio, indicating potential upside from current levels. (techdows.com)
Institutional investors, such as Woodline Partners LP, have significantly increased their holdings in 89bio, reflecting confidence in the company's prospects. (marketbeat.com)
In April 2025, 89bio reported a quarterly loss of $1.02 per share, missing analysts' expectations and raising concerns about its financial performance. (defenseworld.net)
Insider selling activity, such as the sale of 15,329 shares by insider Quoc Le-Nguyen in April 2025, may signal a lack of confidence in the company's near-term prospects. (defenseworld.net)
The biotechnology sector is highly competitive, and 89bio's lead product candidate, pegozafermin, faces potential challenges from existing and emerging therapies, which could impact its market share and revenue potential.
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

89bio, Inc Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

89bio, Inc Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ETNB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs